GSK reported core earnings of 59 cents per American ... Juluca rose 10% while Dovato was up 27% in the quarter. Rukobia sales rose 46% in the quarter. Sales of new long-acting medicines, Cabenuva ...

Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

GSK reported core earnings of 59 cents per American ... Juluca rose 10% while Dovato was up 27% in the quarter. Rukobia sales rose 46% in the quarter. Sales of new long-acting medicines ...

The market was pleased with the recent earnings report from GSK plc (LON:GSK), despite the profit numbers being soft. However, we think the company is showing some signs that things are more ...

As with other drugs, Rukobia (fostemsavir) can cause side effects, such as nausea. If you are not able to tolerate side effects of Rukobia, talk with your doctor or pharmacist. Rukobia ...

LONDON, - British drugmaker GSK will no longer set diversity targets, it said on Thursday, as it became the latest company to scale back or abandon such goals in response to the U.S. president's ...

The usual Rukobia (fostemsavir) dosage for HIV is 600 mg twice per day. Take the Rukobia dosage your doctor prescribes. Doctors prescribe Rukobia (fostemsavir) to treat HIV in certain adults.

Now, GSK is ready to play catch-up after nabbing its own FDA approval. The FDA approved the British drugmaker's Penmenvy vaccine to protect people ages 10 to 25 against meningococcal serogroups A ...

GSK's revenue and EPS exceeded my expectations and those of analysts, thanks to the strong performance of its oncology and HIV franchises. So, Ojjaara/Omjjara sales amounted to $150 million in the ...